<DOC>
	<DOCNO>NCT01417091</DOCNO>
	<brief_summary>This randomize , open label intra-patient dose escalation study evaluate safety tolerability , pharmacokinetics , pharmacodynamics BPS804 adult osteogenesis imperfecta ( OI ) . Pharmacodynamic effect determine serological biomarkers radiologic assessment . In addition , tolerability pharmacokinetics ( PK ) evaluate . Twelve 15 patient enrol .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics BPS804 Osteogenesis Imperfecta</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<criteria>Osteogenesis imperfecta Two previous fracture Bone mineral density Zscore â‰¤ 1.0 &gt; 4.0 Open epiphysis Fracture within last 2 week Treatment bisphosphonates/teriparatide ( last 6 month ) Surgery within last year Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Brittle bone disease</keyword>
	<keyword>inherit</keyword>
	<keyword>connective tissue disorder</keyword>
	<keyword>fracture</keyword>
</DOC>